Location: South Korea
Drug Type: Stem Cell Therapy
Conditions: ALS, Alzheimer’s disease, stroke
Mechanism Type: Neuroprotection
Mechanism: The Neurostem therapy consists of mesenchymal stem cells derived from allogeneic umbilical cord blood that are believed to confer therapeutic benefit by inducing the release of therapeutic proteins (i.e.: anti-apoptotic, anti-inflammatory and anti-oxidative stress) from endogenous cells through paracrine actions. The treatment is first being developed to treat Alzheimer’s type dementia, but the company aims to also apply it to ALS and stroke.
U.S. Status for ALS: N/A
 Stem Cell Products – Neurostem. Medipost America, 2015. Accessed 11 Mar 2016 from http://medipostamerica.com/stem-cell-products-overview/adult-stem-cell-drugs/neurostem/.
 Safety and Exploratory Efficacy Study of NEUROSTEM Versus Placebo in Patients With Alzheimer’s Disease. ClinicalTrials.gov, 6 Jan 2016. Accessed 11 Mar 2016 from https://clinicaltrials.gov/ct2/show/NCT02054208.
Last updated March 11th, 2019